李 暉, 戴孝森, 侯德文, 王進(jìn)昆
(1. 四川省遂寧市中醫(yī)院 腦病中心神經(jīng)外科, 四川 遂寧, 629000;2. 昆明醫(yī)科大學(xué)第一附屬醫(yī)院 神經(jīng)外科, 云南 昆明, 650032)
早期微孔手術(shù)治療中小量基底節(jié)腦出血后腦水腫的療效及對(duì)血清炎性因子的影響
李 暉1, 戴孝森1, 侯德文1, 王進(jìn)昆2
(1. 四川省遂寧市中醫(yī)院 腦病中心神經(jīng)外科, 四川 遂寧, 629000;2. 昆明醫(yī)科大學(xué)第一附屬醫(yī)院 神經(jīng)外科, 云南 昆明, 650032)
目的 探討早期微孔手術(shù)治療中小量基底節(jié)腦出血后腦水腫的療效及對(duì)患者血清炎性因子的影響。方法 將中小量基底節(jié)腦出血患者104例隨機(jī)分為對(duì)照組與觀察組各52例。對(duì)照組采用內(nèi)科保守治療,觀察組采用早期微孔手術(shù)治療。觀察2組治療后3、14 d的腫體體積及血腫清除時(shí)間; 檢測(cè)2組治療前、治療后3 d血清中白細(xì)胞介素-6(IL-6)、白介素-1β(IL-1β)及腫瘤壞死因子-α(TNF-α)水平; 治療前、治療后3周運(yùn)用美國國立衛(wèi)生研究院卒中量表(NIHSS)量表、日常生活能力表Barthel指數(shù)(BI)評(píng)估患者神經(jīng)功能。結(jié)果 治療后3、14 d, 觀察組腫體體積較對(duì)照組顯著減小(P<0.05), 腫體清除時(shí)間顯著短于對(duì)照組(P<0.01); 治療后3 d, 2組血清IL-6、IL-1β及TNF-α水平顯著下降,且觀察組下降更為顯著(P<0.05或P<0.01); 治療后3周, 2組的NIHSS評(píng)分降低, BI指數(shù)升高,且觀察組改善程度更顯著(P<0.05)。結(jié)論 早期微孔手術(shù)可明顯減輕腦出血后腦水腫程度,對(duì)患者神經(jīng)功能恢復(fù)有較大優(yōu)勢(shì)。
微孔手術(shù); 中小量基底節(jié)腦出血后腦水腫; 臨床療效; 血清炎性因子; 神經(jīng)功能
非外傷原因造成的腦實(shí)質(zhì)內(nèi)血管破裂出血為腦出血,占腦卒中的15%~30%[1]。基底節(jié)腦出血后腦水腫多發(fā)于高血壓患者,若不及時(shí)治療可能造成腦組織缺血缺氧,加重神經(jīng)功能損傷,甚至導(dǎo)致患者死亡[2-3]。以往對(duì)基底節(jié)腦出血后腦水腫常采用內(nèi)科保守治療,但易復(fù)發(fā)。本研究探討早期微孔手術(shù)治療腦出血后腦水腫的療效及對(duì)患者血清炎性因子的影響,現(xiàn)報(bào)告如下。
1.1 一般資料
選取2014年10月—2015年12月收治的中小量基底節(jié)腦出血患者104例,均符合腦出血診斷標(biāo)準(zhǔn)[4], 經(jīng)CT掃描確診為基底出血,出血量19~28 mL,平均(26.77±5.75)mL。排除標(biāo)準(zhǔn): ① 伴有腦室積血、蛛網(wǎng)膜下腔出血和顱內(nèi)多發(fā)出血患者; ② 臨床體征較輕者; ③伴有嚴(yán)重心肺功能障礙患者。將患者隨機(jī)分為對(duì)照組和觀察組各52例。觀察組中男26例,女26例; 年齡43~65歲,平均(54.10±6.02)歲; 美國國立衛(wèi)生研究院卒中量表(NIHSS)評(píng)分3~23分,平均(17.40±3.71)分; 伴有嗜睡癥狀24例,淺昏迷癥狀21例,中度昏迷癥狀7例。對(duì)照組中男24例,女28例; 年齡45~68歲,平均(55.16±6.29)歲; NIHSS評(píng)分3~22分,平均(16.95±3.66)分; 伴有嗜睡癥狀23例,淺昏迷癥狀22例,中度昏迷癥狀7例。2組患者性別、年齡及病情等方面無顯著差異(P>0.05), 具有可比性。
1.2 方法
2組均給予控制血壓、降低顱內(nèi)壓、營養(yǎng)神經(jīng)及抗感染等治療。對(duì)照組行內(nèi)科保守治療,觀察組入院24 h內(nèi)行早期微孔手術(shù),即顱內(nèi)微穿刺引流手術(shù)。患者消毒麻醉后經(jīng)顱骨鉆孔探入穿刺針接引流管,根據(jù)CT定位,首次血腫液抽取量控制在血腫體積50%左右,術(shù)后復(fù)查,當(dāng)血腫體積不足20%時(shí)即可拔除穿針刺。
1.3 觀察指標(biāo)
記錄治療3、14 d后2組血腫及水腫體積。治療前、治療后3 d采用ELISA法檢測(cè)血清中白細(xì)胞介素-6(IL-6)、白介素-1β(IL-1β)及腫瘤壞死因子-α(TNF-α)水平。治療前、治療后3周運(yùn)用美國國立衛(wèi)生研究院卒中量表(NIHSS)量表評(píng)估神經(jīng)功能缺損程度,日常生活能力表Barthel指數(shù)(BI)評(píng)估日常生活能力。
治療后3、14 d, 2組血腫水腫體積均減少,觀察組的腫體體積顯著低于對(duì)照組(P<0.05),腫體完全清除時(shí)間顯著短于對(duì)照組(P<0.01)。見表1。治療后3 d, 2組血清IL-6、IL-1β及TNF-α水平顯著下降,且觀察組下降程度較對(duì)照組更顯著(P<0.05或P<0.01)。見表2。2組治療前NHISS評(píng)分、BI指數(shù)無顯著差異(P>0.05)。治療后3周,2組NHISS評(píng)分顯著下降(P<0.05), BI指數(shù)顯著上升(P<0.05), 且觀察組改善程度顯著優(yōu)于對(duì)照組(P<0.05)。見表3。
自發(fā)性基底節(jié)腦出血伴有炎性細(xì)胞因子反應(yīng)加劇,這是由血腫擠壓周圍組織使水腫加重,中性粒細(xì)胞遷移聚集導(dǎo)致的。研究[5-6]表明,凝血酶、纖維蛋白酶降解物和補(bǔ)體系統(tǒng)應(yīng)激反應(yīng)在腦出血后誘發(fā)機(jī)體產(chǎn)生一系列急性炎癥反應(yīng)。適度炎癥反應(yīng)有利于修復(fù)損傷組織,但炎性因子瀑布樣爆發(fā)性反應(yīng)可能加重繼發(fā)性腦損傷病情,對(duì)腦出血患者的肢體功能恢復(fù)不利。基底節(jié)腦出血后腦水腫多發(fā)于高血壓患者[7-9], 該病具有破壞性、致殘率和死亡率高等特點(diǎn)。一般認(rèn)為,血腫體積>30 mL為手術(shù)治療指征,血腫體積≤30 mL采用常規(guī)保守治療,但保守治療后仍有部分血腫殘留。骨瓣成形開顱手術(shù)可有效清除血腫,但該手術(shù)作為一種入侵性操作,會(huì)對(duì)正常腦組織帶來一定損傷,且術(shù)后易高發(fā)腦水腫。微孔手術(shù)能有效清除血腫,降低顱內(nèi)壓。早期微孔手術(shù)可在腦水腫達(dá)高峰前逐步清除血腫。

表1 2組治療后血腫、水腫情況比較
與對(duì)照組比較, *P<0.05, **P<0.01。

表2 2組血清IL-6、IL-1β及TNF-α水平比較
與治療前比較, *P<0.05, **P<0.01; 與對(duì)照組比較, ##P<0.01。

表3 治療前后2組NHISS和BI評(píng)分比較 分
與治療前比較, *P<0.05; 與對(duì)照組比較, #P<0.05。
本研究中,觀察組治療后3、14 d血腫、水腫體積小于對(duì)照組,腫體完全清除時(shí)間顯著短于對(duì)照組,提示微孔手術(shù)能盡早清除顱內(nèi)血腫,與陳國峰[10]、呂莉等[11]的研究結(jié)果相符。IL-6、IL-1β、TNF-α是常見的炎性反應(yīng)因子,能夠反映機(jī)體發(fā)生炎癥反應(yīng)的程度。IL-6、IL-1β及TNF-α水平輕度升高是組織細(xì)胞防御修復(fù)的結(jié)果[12]。若炎性因子水平過高則超出機(jī)體防御修復(fù)的界限,會(huì)對(duì)機(jī)體組織細(xì)胞產(chǎn)生二次瀑布樣爆發(fā)性炎性反應(yīng),使神經(jīng)元細(xì)胞損傷加劇。既往研究[12]表明,治療后72 h的水平變化與神經(jīng)功能損傷程度密切相關(guān)。本研究治療后72 h, 2組血清中的IL-6、IL-1β、TNF-α水平較治療前下降,且觀察組下降更為顯著,可見治療后72 h機(jī)體內(nèi)的炎癥反應(yīng)明顯減弱。觀察組NIHSS評(píng)分降低,BI指數(shù)上升,可能與微孔手術(shù)緩解水腫狀況,降低血清炎性因子水平,減輕繼發(fā)性腦損傷有關(guān)。
[1] 崔向?qū)? 李玉波, 李妍, 等. 活血、利水中藥對(duì)腦出血大鼠腦組織腫瘤壞死因子-α、核轉(zhuǎn)錄因子KB及水通道蛋白-4表達(dá)的影響[J]. 中國中西醫(yī)結(jié)合雜志, 2012, 32(2): 203-208.
[2] 孫皓, 郭富強(qiáng), 王多姿, 等. 補(bǔ)陽還五湯化裁對(duì)大鼠腦出血后腦水腫的影響[J]. 中國醫(yī)藥導(dǎo)報(bào), 2013, 10(12): 22-23, 26.
[3] 蘆戩, 王黃鎖, 吉宏明, 等. 冠心寧注射液對(duì)腦出血術(shù)后腦水腫的影響及療效分析[J]. 山西醫(yī)藥雜志, 2013, 42(11): 1289-1290.
[4] 中華中醫(yī)藥學(xué)會(huì). 腦出血中醫(yī)診療指南[J]. 中國中醫(yī)藥現(xiàn)代遠(yuǎn)程教育, 2011, 09(23): 110-112.
[5] Rastogi V, Donnangelo LL, Asaithambi G, et al. Recurrence of Lobar Hemorrhage: A Red Flag for Cerebral Amyloid Angiopathy-relatedInflammation[J]. Innovations in Clinical Neuroscience, 2015, 12(5/6): 20-26.
[6] Qin J, Ma X, Qi H, et al. Transplantation of Induced Pluripotent StemCells Alleviates Cerebral Inflammation and Neural Damage in Hemorrhagic Stroke[J]. Plos One, 2015, 10(6): 131-137.
[7] Xing H Q, Moritoyo T, Mori K, et al. Expressions of serum inflammatory cytokines and their relationship with cerebral edema in patients with acute basal ganglia hemorrhage[J]. Eur Rev Med Pharmacol Sci, 2016, 20(13): 2868-2871.
[8] Wang G Q, Li S Q, Huang Y H, et al. Can minimal invasive puncture and drainage for hypertension spontaneous basal ganglia intracerebral hemorrhage improve patient outcome: A prospective non-randomized comparative study[J]. Medical Journal of Chinese People's Liberation Army, 2014, 39(7): 531-541.
[9] Cheripelli B K, Huang X, Macisaac R, et al. Interaction of Recanalization, Intracerebral Hemorrhage, and Cerebral Edema After Intravenous Thrombolysis[J]. Stroke, 2016, 47(7): 1761-1767.
[10] 陳國峰, 陳志斌. 早期微孔手術(shù)對(duì)中小量基底節(jié)腦出血后腦水腫及預(yù)后影響的研究[J]. 中國醫(yī)藥指南, 2012, 11(10): 263-264.
[11] 呂莉. 早期微孔手術(shù)與內(nèi)科保守治療對(duì)患者中小量基底節(jié)腦出血后腦水腫及預(yù)后影響[J]. 中國老年學(xué)雜志, 2015, 7(35): 3754-3755.
[12] Damlar I, Esen E, Tali U. Effects of glucosamine-chondroitin combination on synovial fluid IL-1β, IL-6, TNF-α and PGE2levels in internal derangements of temporomandibular joint[J]. Medicina oral, patologia oral y cirugia bucal, 2015, 20(3): e278-e283.
Clinical efficacy of early micro-porous surgery in treatment of patients with encephaledema after small- and moderate-volume basal ganglia hemorrhage and its influence on serum inflammatory factors
LI Hui1, DAI Xiaosen1, HOU Dewen1, WANG Jinkun2
(1.DepartmentofNeurosurgeryinEncephalopathyCenter,SuiningHospitalofTCM,Suining,Sichuan, 629000; 2.DepartmentofNeurosurgery,TheFirstAffiliatedHospitalofKunmingMedicalUniversity,Kunming,Yunnan, 650032)
Objective To explore the clinical efficacy of early micro-porous surgery in the treatment of patients with encephaledema after small- and moderate-volume basal ganglia hemorrhage and its influence on serum inflammatory factors. Methods A total of 104 patients with small- and moderate-volume basal ganglia hemorrhage were randomly divided into control group and observation group, 52 cases in each group. Control group was treated with conventional treatment, while observation group was treated with early micro-porous surgery. The volume of encephaledema and clearance time of hematoma 3 d and 14 d after treatment were observed in both groups. The levels of serum interleukin-6 (IL-6), IL-1β and tumor necrosis factors-α (TNF-α) were detected before treatment and 3 d after treatment in both groups. National Institutes of Health Stroke Scale (NIHSS) and Activities of Daily Life Function Assessment Scale Barthel index (BI) were used before and 3 weeks after treatment to evaluate patients′ neurological function. Results The 3 d and 14 d after treatment, observation group was significantly smaller in volume of encephaledema (P<0.05) and shorter in clearance time of hematoma (P<0.01) when compared with control group. Three days after treatment, levels of serum IL-6, IL-1β and TNF-α decreased significantly in both groups, which decreased more significantly in observation group than in control group (P<0.05 orP<0.01). Three weeks aftertreatment, NIHSS score decreased significantly while BI increased significantly in both groups, which improved more significantly in observation group than in control group (P<0.05). Conclusion Early micro-porous surgery can significantly relieve the severity of encephaledema after intra-cerebral hemorrhage, and has greater advantages in recovering patients′ neurological function.
micro-porous surgery; encephaledema after small- and moderate-volume basal ganglia hemorrhage; clinical efficacy; serum inflammatory factors; neurological function
2016-10-19
王進(jìn)昆, E-mail: 497563368@qq.com
R 743.34
A
1672-2353(2017)01-065-03
10.7619/jcmp.201701019